Pan Cancer
Guiding treatment for solid tumors
In a rapidly changing landscape of genetic technology and cancer treatment options, the journey patients take through diagnosis and treatment is highly individual. At Mayo Clinic, we recognize a one-size-fits-all approach doesn't meet the needs of every patient. Multiple factors, such as history, diagnosis, specimen availability, and prognosis affect which test a patient receives.
PAN CANCER test menu
Pan Cancer
Our comprehensive MayoComplete solid tumor panel analyzes 515 genes for mutations, rearrangements, amplifications, homozygous gene deletions, and/or transcript variants as well as evaluates for tumor mutation burden (TMB) and microsatellite instability (MSI) status to provide detailed insights on diagnosis, prognosis, and treatment response. Because obtaining sufficient tissue for multiple molecular and histological tests can be challenging, we have optimized specimen requirements by reducing the amount of FFPE tissue required and accept cytology as an alternative specimen type.
Key testing
Advantages
- Assists in tumor profiling for diagnosis, predicting prognosis, and identifying targeted therapies for the treatment and management of patients with solid tumors.
- Identifies sequence alterations in 515 genes, amplification of 96 genes, homozygous deletion of 133 genes, as well as detection of fusions involving 55 genes and complete inactivation of 31 tumor suppressor genes.
- Evaluates tumor mutation burden (TMB) status and microsatellite instability (MSI).
- Can assist in determining eligibility for clinical trials.
- Can be performed on both formalin-fixed, paraffin-embedded (FFPE) tissue and cytology specimens, including smears.
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.